Treatment with zuranolone, a novel oral antidepressant for postpartum depression, raises important questions for breastfeeding individuals. While recent studies show minimal transfer into breast milk, we do not yet have enough information to recommend breastfeeding while taking zuranolone.
An individualized, collaborative approach to decision-making helps mothers navigate complex choices with confidence, ensuring the well-being of their child, while attending to their own mental health. Â
New documentary illuminates the faces and voices of postpartum depression across America.
While zuranolone may show promise for the treatment of depressive episodes in patients with bipolar disorder, more research is needed.
In a recent study from Mass General Hospital, researchers examined whether information included in the medical record at the time of discharge after delivery could help us to identify individuals at increased risk for postpartum depression.
Postpartum anxiety is a common and often under-recognized condition that affects a substantial proportion of new mothers.
For new moms, breastfeeding is often more difficult than anticipated. In fact, feeding challenges are actually the norm, not the exception.
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on optimizing the likelihood of treatment for postpartum depression with Ob.Gyn News on August 27, 2024.
The Healthy Mother - Healthy Baby intervention delivered by non-specialists cuts postpartum depression risk by 81% through anxiety-focused care.
Blood levels of neuroactive steroids during the third trimester of pregnancy may predict increased risk of postpartum depression, offering possibility for early intervention.
